The nitroimidazole ronidazole (1-methyl-2-carbamoyloxymethyl-5-nitroimidazole; Ridzol, Merck & Co., Inc.) has been shown to be useful in the control of enterohepatitis in turkeys (1, 2) and to have activity against experimentally induced mycoplasmal infections in turkeys and chickens (Skelly et al., Bacteriol. Proc., p. 86, 1969; Skelly and Kasowsky, Bacteriol. Proc., p. 83, 1970; Skelly et al., Abstr., Xth Int. Congr. Microbiol., 1970 Table 2 compares the in vitro inhibitory activity of several antiparasitic compounds against a strain of Escherichia coli. Under these test conditions, only aminitrozole and ronidazole inhibited the growth of E. coli, and only ronidazole was bactericidal against large inocula. The data also show that the size of the inoculum used must be increased to 107 cells/ml before there is any effect at all on the minimum inhibitory concentration of the active antiparasitic compounds. Table 3 shows that ronidazole has antibacterial activity in vivo in all cases in which in vitro activity had been shown except against Staphylococcus aureus. Aminitrozole that had some in vitro activity against E. coli was not active in vivo at nontoxic levels.
We conclude from these tests that ronidazole, in addition to its antiparasitic and antimycoplasmal activity, has some antibacterial activity that can be demonstrated in experimental infections in the mouse. 
